Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Miyake, Makito ^a   Goodison, Steve ^a,b   Lawton, Adrienne ^c   Zhang, Ge ^a   Gomes Giacoia, Evan ^a   Rosser, Charles J ^a,b,d  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b Nonagen Bioscience Corp   (United States)

^c ORLANDO HEALTH   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; ERK1 2; Erythropoietin; Hypoxia; JAK2; Renal

Indexed keywords

CYCLIN D1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL CYCLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY TUMOR; LUNG CANCER; LYMPHOMA; PHENOTYPE; PHOSPHORYLATION; PROSTATE CANCER; THYROID CANCER; TISSUE MICROARRAY; TUMOR XENOGRAFT; UTERUS CANCER;

ANIMALS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; ERYTHROPOIETIN; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; RANDOM ALLOCATION; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84883276549     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-65     Document Type: Article

References (61)

1. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL, J Biol Chem 1996 271 17771 17778 10.1074/jbc.271.30.17771 8663540 (Pubitemid 26250751)
2. Hypoxia-inducible factors in physiology and medicine. Semenza GL, Cell 2012 148 399 408 10.1016/j.cell.2012.01.021 22304911
3. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH, Oncogene 2000 19 5435 5443 10.1038/sj.onc.1203938 11114720 (Pubitemid 32000910)
4. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M, J Biol Chem 2003 278 11032 11040 10.1074/jbc.M208681200 12538644 (Pubitemid 36792653)
5. VHL and HIF signalling in renal cell carcinogenesis. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP, J Pathol 2010 221 125 138 10.1002/path.2689 20225241
6. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG, Nat Cell Biol 2000 2 423 427 10.1038/35017054 10878807
7. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Groulx I, Lee S, Mol Cell Biol 2002 22 5319 5336 10.1128/MCB.22.15.5319-5336.2002 12101228 (Pubitemid 34755745)
8. The molecular biology of erythropoietin. Lacombe C, Mayeux P, Nephrol Dial Transplant 1999 14 Suppl 2 22 28 10463199 (Pubitemid 29154936)
9. Studies on the liver to kidney switch of erythropoietin production. Zanjani ED, Ascensao JL, McGlave PB, Banisadre M, Ash RC, J Clin Invest 1981 67 1183 1188 10.1172/JCI110133 7204572 (Pubitemid 11090560)
10. Development and characterization of novel erythropoiesis stimulating protein (NESP). Egrie JC, Browne JK, Br J Cancer 2001 84 Suppl 1 3 10 11308268 (Pubitemid 32453429)
11. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P, EPO-INT-45 Study Group, Br J Cancer 2006 94 947 954 10.1038/sj.bjc.6603004 16570051
12. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H, Lancet 2003 362 1255 1260 10.1016/S0140-6736(03)14567-9 14575968 (Pubitemid 37324251)
13. Erythropoietin receptor characteristics on primary human erythroid cells. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T, Blood 1991 77 2583 2590 1646044
14. Erythropoietin receptor mRNA expression in human endothelial cells. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT, Proc Natl Acad Sci USA 1994 91 3974 3978 10.1073/pnas.91.9.3974 8171022 (Pubitemid 24139555)
15. Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ, BMC Cancer 2013 13 322 10.1186/1471-2407-13-322 23815949
16. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ, Mol Cancer Ther 2007 6 101 111 10.1158/1535-7163.MCT-06-0367 17237270 (Pubitemid 46206672)
17. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M, Carcinogenesis 2007 28 529 536 16920734 (Pubitemid 46523348)
18. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D, Mol Biol Cell 2002 13 1977 2000 10.1091/mbc.02-02-0030. 12058064 (Pubitemid 34651487)
19. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ, Urol Oncol 2011 29 421 429 10.1016/j.urolonc.2009.04.009 19576799
20. Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors. Samoszuk MK, Walter J, Mechetner E, J Histochem Cytochem 2004 52 837 839 10.1369/jhc.4B6248.2004 15150293 (Pubitemid 38703139)
21. Expression of erythropoietin and its receptor in human renal cell carcinoma. Papworth K, Bergh A, Grankvist K, Ljungberg B, Rasmuson T, Tumour Biol 2009 30 86 92 10.1159/000216844 19407488
22. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Hedley BD, Allan AL, Xenocostas A, Clin Cancer Res 2011 17 6373 6380 10.1158/1078-0432.CCR-10-2577 21750199
23. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN, Cell 1993 74 227 236 10.1016/0092-8674(93)90414-L 8343951 (Pubitemid 23221699)
24. The erythropoietin receptor in normal and cancer tissues. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ, Crit Rev Oncol Hematol 2008 67 39 61 10.1016/j.critrevonc.2008.03.006 18434185
25. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ, Int J Cancer 2008 122 274 280 10.1002/ijc.23068 17893874 (Pubitemid 350234712)
26. Induction of signaling in non-erythroid cells by pharmacological levels of erythropoietin. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR, Neurodegener Dis 2006 3 94 100 10.1159/000092099 16909043 (Pubitemid 43760374)
27. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group, Lancet Oncol 2005 6 757 764 10.1016/S1470-2045(05)70292-8 16198981 (Pubitemid 41430716)
28. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H, Br J Cancer 2010 102 301 315 10.1038/sj.bjc.6605498 20051958
29. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, Pajonk F, J Clin Oncol 2006 24 4708 4713 10.1200/JCO.2006.06.2737 17028293 (Pubitemid 46630934)
30. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Ciocca DR, Calderwood SK, Cell Stress Chaperones 2005 10 86 103 10.1379/CSC-99r.1 16038406 (Pubitemid 40942470)
31. Renal cell carcinoma and erythropoietin. Sungur C, Ann Intern Med 1995 123 732 733 7574237
32. Treatment of advanced kidney cancer using recombinant erythropoietin. Morere JF, Bouillet T, Piperno-Neumann S, Tourani JM, Brunet A, Hennebelle F, Bareau JL, Prog Urol 1997 7 399 402 9273066 (Pubitemid 127525324)
33. Functional significance of erythropoietin in renal cell carcinoma. Morais C, Johnson DW, Vesey DA, Gobe GC, BMC Cancer 2013 13 14 10.1186/1471-2407-13-14 23305401
34. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. the European study group of erythropoietin (epoetin beta) treatment in multiple myeloma and non-Hodgkin's lymphoma. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D, Blood 1996 87 2675 2682 8639883 (Pubitemid 26102216)
35. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group, J Clin Oncol 2001 19 2865 2874 11387359 (Pubitemid 32538196)
36. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Pronzato P, Cortesi E, Van Der Rijt CC, Bols A, Moreno-Nogueira JA, De Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R, EPO-INT-47 Study Group, Oncologist 2010 15 935 943 10.1634/theoncologist.2009-0279 20798194
37. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group, J Natl Cancer Inst 2002 94 1211 1220 10.1093/jnci/94.16.1211 12189224 (Pubitemid 34993871)
38. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altés A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ, Darbepoetin Alfa 20000161 Study Group, Br J Haematol 2003 122 394 403 10.1046/j.1365-2141.2003.04448.x 12877666 (Pubitemid 36951623)
39. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP, J Support Oncol 2003 1 131 138 15352656
40. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Chang J, Couture F, Young S, McWatters KL, Lau CY, J Clin Oncol 2005 23 2597 2605 15452188 (Pubitemid 46179448)
41. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ, J Clin Oncol 2005 23 9377 9386 10.1200/JCO.2005.01.8507 16361638
42. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E, J Clin Oncol 2005 23 5960 5972 10.1200/JCO.2005.06.150 16087945
43. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Osterborg A, Brandberg Y, Hedenus M, Br J Haematol 2005 129 206 209 10.1111/j.1365-2141.2005. 05440.x 15813848 (Pubitemid 40562441)
44. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF, J Clin Oncol 2005 23 2606 2617 15452187 (Pubitemid 46179449)
45. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V, J Clin Oncol 2010 28 2239 2245 10.1200/JCO.2009.25.1835 20368566
46. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU, J Clin Oncol 2008 26 592 598 10.1200/JCO.2007.11.5378 18235117 (Pubitemid 351264353)
47. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF, J Clin Oncol 2008 26 2342 2349 10.1200/JCO.2007.15.0748 18467726
48. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Strauss HG, Haensgen G, Dunst J, Hayward CR, Burger HU, Scherhag A, Koelbl H, Int J Gynecol Cancer 2008 18 515 524 10.1111/j.1525-1438.2007.01032.x 17645506 (Pubitemid 351668300)
49. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs. above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci JA 3rd, Begg AC, Gynecol Oncol 2008 108 317 325 10.1016/j.ygyno.2007.10. 011 18037478
50. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H, Neoplasia 2008 10 932 939 18714393
51. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Silver DF, Piver MS, Gynecol Oncol 1999 73 280 284 10.1006/gyno.1999.5368 10329047 (Pubitemid 29215744)
52. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M, J Cancer Res Clin Oncol 2001 127 346 350 10.1007/s004320000215 11414194 (Pubitemid 32453676)
53. Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Fujisue Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Azuma H, Asahi M, Oncol Lett 2013 5 1765 23833638
54. Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Alexanian A, Rufanova VA, Miller B, Flasch A, Roman RJ, Sorokin A, Anticancer Res 2009 29 3819 3824 19846914
55. Metastatic behavior of human tumor cell lines grown in the nude mouse. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR, Cancer Res 1984 44 3522 3529 6744277 (Pubitemid 14098607)
56. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1# and -2# in sporadic clear cell renal carcinoma. Gong K, Zhang N, Zhang K, Na Y, Int J Mol Med 2010 26 907 912 21042786
57. Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma. Ito K, Yoshii H, Asano T, Horiguchi A, Sumitomo M, Hayakawa M, Asano T, Exp Ther Med 2012 3 937 944 22969996
58. Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma. Feng CC, Ding GX, Song NH, Li X, Wu Z, Jiang HW, Ding Q, Tumour Biol 2013 19
59. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Clin Cancer Res 2007 13 7388 7393 10.1158/1078-0432.CCR-07-0411 18094421
60. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle. Mannello F, Tonti GA, Oncologist 2008 13 761 10.1634/theoncologist.2008-0110 18596367
61. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N, Blood 2002 99 102 110 10.1182/blood.V99.1.102 11756159 (Pubitemid 34532971)